About
Therapeutic gene editing (CRISPR)
Areas of Focus
Categories
Biologics & BiopharmaceuticalStem Cell & Cellular TherapyBoston & New England
Team (18)
Aron Stein, Ph.D.
Senior Vice President, Regulatory Affairs
Intellia Therapeutics
executive
Bill Chase
Independent Director
Intellia Therapeutics
board_member
Birgit Schultes, Ph.D.
Executive Vice President,Chief Scientific Officer
Intellia Therapeutics
executive
Brian Goff
Independent Director
Intellia Therapeutics
board_member
David Lebwohl, M.D.
Executive Vice President,Chief Medical Officer
Intellia Therapeutics
executive
Edward Dulac
Executive Vice President,Chief Financial Officer
Intellia Therapeutics
executive
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
9
As Collaborator
1
Total Enrollment
1,292
By Phase
PHASE3: 3PHASE1/PHASE2: 4PHASE1: 1
By Status
RECRUITING: 4ACTIVE_NOT_RECRUITING: 3WITHDRAWN: 1ENROLLING_BY_INVITATION: 1TERMINATED: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
Today
Hover over trial bars to see details
Recent Trials
NCT06634420Lead Sponsor
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
PHASE3Active, not recruiting
60 participants
Started: Jan 15, 2025 · Completed: Sep 30, 2027
NCT06672237Lead Sponsor
A Phase 3 Study of NTLA-2001 in ATTRv-PN
PHASE3Recruiting
50 participants
Started: Nov 22, 2024 · Completed: Aug 31, 2028
NCT06622668Lead Sponsor
NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
PHASE1/PHASE2Withdrawn
Started: Nov 20, 2024 · Completed: Jan 9, 2025
NCT06379789Collaborator
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
PHASE1/PHASE2Recruiting
130 participants
Started: Sep 11, 2024 · Completed: Dec 17, 2032
NCT06262399Lead Sponsor
Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002
N/AEnrolling by invitation
100 participants
Started: Apr 12, 2024 · Completed: Apr 30, 2040
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...